TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
A phase 2 trial of Trastuzumab in colorectal cancer, run by Suzhou Teligene Ltd., now recruiting.
Overview
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06589830 by Suzhou Teligene Ltd., with 80 participants planned, started 2025-05-13 and due to reach its primary completion in 2026-10. Interventions recorded: TL938 Capsules, Trastuzumab. Conditions listed: Colorectal Cancer Metastatic, Advanced Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Shares Trastuzumab, Colorectal cancer.
- TrialMOUNTAINEER & MOUNTAINEER-03
Shares Trastuzumab, Colorectal cancer.
- TrialBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit
Shares Trastuzumab, Colorectal cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Trastuzumab, Colorectal cancer.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Trastuzumab, Colorectal cancer.
- InstitutionInstituto Alexander Fleming
Shares Trastuzumab, Colorectal cancer.
- InstitutionNSABP Foundation
Shares Trastuzumab, Colorectal cancer.
- InstitutionIstituto di Candiolo IRCCS (FPO)
Shares Trastuzumab, Colorectal cancer.